HAMBURG, Germany, May 9, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that its research alliance with Boehringer Ingelheim has achieved a twelfth milestone triggering a payment of EUR 2.0 million to Evotec. The milestone reached was on the transition of an oncology programme into lead optimisation.
